Dianthus Therapeutics
DNTH
90 hedge funds and large institutions have $418M invested in Dianthus Therapeutics in 2021 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 26 increasing their positions, 29 reducing their positions, and 14 closing their positions.
306% more call options, than puts
Call options by funds: $739K | Put options by funds: $182K
64% more capital invested
Capital invested by funds: $255M → $418M (+$163M)
0.34% more ownership
Funds ownership: 4.21% → 4.55% (+0.34%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less funds holding
Funds holding: 92 → 90 (-2)
10% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 29
14% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 14
Top Buyers
| 1 |
O
OrbiMed
New York
|
+$9.98M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$7.1M |
| 3 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$6.31M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.05M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
+$5.85M |
Top Sellers
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$7.84M |
| 2 |
Morgan Stanley
New York
|
-$3.85M |
| 3 |
Renaissance Technologies
New York
|
-$1.68M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.51M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$985K |
DNTH Hedge Fund Activity: Q1 2021 in Review
90 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Dianthus Therapeutics (DNTH) for Q1 2021, worth a combined $418M — up 64% from $255M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of DNTH and 12 opened new positions — a net loss of 2 holders — while 29 trimmed existing stakes and 26 added.
The largest buyer was OrbiMed, opening a new position worth an estimated $9.98M. The largest seller was Eventide Asset Management, exiting entirely with an estimated $7.84M sold.
- 90 institutional investors held Dianthus Therapeutics (DNTH) as of Q1 2021, down from 92 in Q4 2020.
- Funds reported $418M of Dianthus Therapeutics stock for Q1 2021, up 64% quarter-over-quarter.
- 12 funds opened new Dianthus Therapeutics positions in Q1 2021 and 14 closed out, a net change of -2 holders.
- The largest Dianthus Therapeutics buyer in Q1 2021 was OrbiMed, an estimated $9.98M added.
- The largest Dianthus Therapeutics seller in Q1 2021 was Eventide Asset Management, an estimated $7.84M sold.
Based on aggregated 13F filings for Q1 2021.